Strategic approaches to enhance the adoption of GLP-1 analogs for diabetes and obesity treatment in India
SP Jain School of Global Management, Mumbai, India.
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(01), 444–457.
Article DOI: 10.30574/wjbphs.2024.19.1.0464
Publication history:
Received on 18 June 2024; revised on 26 July 2024; accepted on 28 July 2024
Abstract:
The introduction of GLP-1 analogs in the Indian market holds great potential for diabetes and obesity management, yet their widespread adoption is hindered by several challenges. These include limited long-term data on cardiovascular and renal safety, high costs, lack of outpatient insurance coverage for major drugs, side effects, drug availability issues, and healthcare professionals' (HCPs) reluctance to prescribe them. In a country where many patients pay out-of-pocket and financial planning for healthcare is inadequate, these barriers are further amplified.
This study, involving a survey of 250 patients, explores the multifaceted landscape of GLP-1 analogs' acceptance in India. It examines dimensions such as financing schemes, market access strategies, internet trading, and the impact of biosimilars on pricing. By addressing gaps in discussions around discounts, rebates, profits, and price transparency, the research aims to identify key factors that could facilitate the early adoption of GLP-1 analogs in the Indian market.
The study advocates for a comprehensive strategy encompassing insurance coverage, patient-centric programs, effective branding, improved drug availability, increased public awareness, and the dissemination of long-term cardiovascular and renal safety data to HCPs. This holistic approach aims to enhance the accessibility of anti-diabetic and anti-obesity products in India, ultimately benefiting a large segment of the population struggling with these conditions. By fostering a deeper understanding and acceptance of GLP-1 among HCPs and patients, the study seeks to pave the way for the successful integration of these innovative therapies into the Indian healthcare system.
Keywords:
GLP-1 Analogs; Diabetes; Obesity; Market Access; Insurance Coverage; Healthcare Professionals; Drug Availability
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0